Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530686 · ClinicalTrials.gov registry record · Phase 1
Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment
A Phase 1 study, sponsored by Baylor Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00530686 is a Phase 1 study that has completed, run by Baylor Research Institute. The registered enrollment target is 1 participants.
The verdict
NCT00530686, a Phase 1 study, has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to assess a novel approach to immunosuppression in allogenic pancreatic islet cell transplant recipients. In addition, the study aims to assess remote site islet processing with culture for pancreatic islet cell transplantation in human subjects.
Interventions
- DRUG Islet cell transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2008-07 |
| Est. Completion | 2017-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530686
The ClinicalTrials.gov registry entry for NCT00530686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor Research Institute, which has 180 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Islet cell transplantation is the first listed.
NCT00530686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00530686 about?
NCT00530686 is a clinical study titled "Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment". The purpose of this study is to assess a novel approach to immunosuppression in allogenic pancreatic islet cell transplant recipients. In addition, the study aims to assess remote site islet processing with culture for pancreatic islet cell transplantation in human subjects.
What is the current status of trial NCT00530686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2008-07. Estimated completion is 2017-04.
What interventions are being tested in trial NCT00530686?
The interventions under investigation include: Islet cell transplantation (DRUG).
Who is sponsoring clinical trial NCT00530686?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.